Strategic Recruitment
Enrollment Achieved
Thoughtful Recruitment: Postpartum depression affects 1 in 7 new mothers—yet reaching those who need support most can be challenging. 1nHealth was brought in to supplement a sponsor’s recruitment efforts for a clinical trial aiming to enroll 72 new mothers experiencing symptoms of postpartum depression. While the inclusion/exclusion criteria were relatively straightforward, reaching this highly specific audience required thoughtful strategy. The sponsor had exhausted traditional methods, so 1nHealth was tasked with identifying new digital pathways, crafting messaging that resonated with real moms, and accelerating enrollment without compromising quality.
Bold Creative: Through A/B testing of the “psychedelic” angle in both copy and imagery, 1nHealth challenged conventional expectations about how to reach new mothers experiencing postpartum depression. In most campaigns, the go-to approach is highly clinical, but that tone can easily blend into the background, especially for women already overwhelmed by their postpartum experience. By testing bold, unexpected creative—like vivid colors and thought-provoking language—we aimed to stop the scroll, spark curiosity, and invite a deeper emotional connection.
Optimizing Speed Without Sacrificing Quality: In fast-moving clinical trials, speed is essential—but rushing recruitment without testing can waste valuable time and resources. By systematically testing different messaging, visuals, and channels, we uncover what truly connects with potential participants. This data-driven approach allows us to fine-tune campaigns quickly, maximizing engagement and enrollment while minimizing screen failures. Even with tight deadlines, ongoing optimization ensures every effort counts, helping trials reach their goals faster and more efficiently.
Exceeding Expectations: 1nHealth sourced the majority of consented patients (54%) and the majority of randomized patients (56%) all with the lowest overall screen fail rate (58%)—finishing 14 months ahead of original LPI expectations. We also achieved the n=72 target by April 2025 and contributed an additional 12 randomizations in the following weeks.
